A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes

Launched by ELI LILLY AND COMPANY · Mar 24, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at two medications, bimagrumab and tirzepatide, to see how well they help people with obesity or being overweight and type 2 diabetes lose weight. The study will also explore whether using these medications together is more effective. If you participate, the study will last about 13 months, and you'll be closely monitored for safety and effectiveness.

To take part in this study, you need to be between 18 and 75 years old, have type 2 diabetes, and have a body mass index (BMI) of 27 or higher, which means you are considered overweight. You should also have maintained a stable weight for the last three months. However, this trial is not for everyone; for instance, if you have certain heart conditions, have had surgery for obesity, or have other specific health issues, you may not be eligible. If you qualify and choose to participate, you'll receive detailed information about what to expect during the study and how it may help you.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Have type 2 diabetes
• • Have a BMI of ≥27 kilograms per square meter (kg/m2)
• • Have had a stable body weight for the 3 months prior to randomization (\<5% body weight gain and/or loss)
• Exclusion Criteria:
• • Have a prior or planned surgical treatment for obesity,
• • Have type 1 diabetes, latent autoimmune diabetes, or history of ketoacidosis or hyperosmolar state or coma
• • Have poorly controlled hypertension
• * Have any of the following cardiovascular conditions within 3 months prior to screening:
• • acute myocardial infarction
• • cerebrovascular accident (stroke)
• • unstable angina, or
• • hospitalization due to congestive heart failure
• • Have a history of New York Heart Association (NYHA) Functional Classification III or IV congestive heart failure
• • Have ongoing or a history of frequent intermittent or chronic tachyarrhythmia syndromes
• • Have ongoing or a history of bradyarrhythmias other than sinus bradycardia
• • Have renal impairment
• • Have a history of symptomatic gallbladder disease within the past 2 years
• • Have signs and symptoms of any liver disease
• • Have a disease or condition known to cause gastrointestinal malabsorption or a known clinically significant gastric emptying abnormality
• • Have a history of acute or chronic pancreatitis
• • Currently taking or have taken medications that may cause significant weight gain or promote weight loss within 3 months prior to screening